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Abstract
Background: Globally, rheumatic heart disease (RHD) remains an important cause of heart disease. In Australia it
particularly affects younger Indigenous and older non-Indigenous Australians. Despite its impact there is limited
understanding of the factors influencing outcome following surgery for RHD.
Methods: The Australian and New Zealand Society of Cardiac and Thoracic Surgeons Cardiac Surgery Database was
analysed to assess outcomes following surgical procedures for RHD and non-RHD valvular disease. The association
with demographics, co-morbidities, pre-operative status, valve(s) affected and operative procedure was evaluated.
Results: Outcome of 1384 RHD and 15843 non-RHD valve procedures was analysed. RHD patients had longer
ventilation, experienced fewer strokes and had more readmissions to hospital and anticoagulant complications.
Mortality following RHD surgery at 30 days was 3.1 % (95 % CI 2.2 – 4.3), 5 years 15.3 % (11.7 – 19.5) and 10 years
25.0 % (10.7 – 44.9). Mortality following non-RHD surgery at 30 days was 4.3 % (95 % CI 3.9 - 4.6), 5 years 17.6 %
(16.4 - 18.9) and 10 years 39.4 % (33.0 - 46.1). Factors independently associated with poorer longer term survival
following RHD surgery included older age (OR1.03/additional year, 95 % CI 1.01 – 1.05), concomitant diabetes
(OR 1.7, 95 % CI 1.1 – 2.5) and chronic kidney disease (1.9, 1.2 – 2.9), longer invasive ventilation time (OR 1.7 if greater
than median value, 1.1– 2.9) and prolonged stay in hospital (1.02/additional day, 1.01 – 1.03). Survival in Indigenous
Australians was comparable to that seen in non-Indigenous Australians.
Conclusion: In a large prospective cohort study we have demonstrated survival following RHD valve surgery in
Australia is comparable to earlier studies. Patients with diabetes and chronic kidney disease, were at particular risk of
poorer long-term survival. Unlike earlier studies we did not find pre-existing atrial fibrillation, being an Indigenous
Australian or the nature of the underlying valve lesion were independent predictors of survival.
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Background
Rheumatic heart disease (RHD) is a condition of global
health importance. It is estimated 15.6 to 19.6 million
people are living with RHD, with almost 80 % of these
residing in low and middle-income countries [1, 2], with
an estimated population prevalence in those countries of
2.5 to 3.2 cases per 1000 [1]. Approximately 1 to 5 % of
people with RHD die each year accounting for 233 000
to 294 000 RHD-related deaths per year, 95 % of these
occurring in low- and middle income countries [1] with
limited facilities to treat advanced disease requiring valve
surgery.
Whilst RHD is now rare in high income countries [3],
except for migrant and older residents, it remains an im-
portant and ongoing cause of preventable heart disease in
Indigenous populations [4]. A recent echocardiographic
screening study of Indigenous Australian (Aboriginal
and Torres Strait Islander) children aged 5–14 years,
found a prevalence of RHD [5] of 8.6 per 1000 (95 %
CI 6.0 – 12.0) with none detected in a comparably
aged non-Indigenous cohort [6].
Surgical intervention remains an important treatment
modality for those with more severe forms of RHD, yet
disparities exist in access to and outcomes following RHD
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surgery [7]. Factors which have been identified as being
associated with outcomes following valve surgery in pa-
tients with RHD-related valve disease include age [8–11],
pre-operative clinical status [8–10, 12–15], pre-existing
atrial fibrillation (AF) [13, 16, 17], left ventricular function
[12–14, 18, 19] and the nature of the underlying valve
lesion [10, 12, 13, 20].
Increasing age has been associated with lower overall
event-free survival [8–11, 21] and operative mortality
[16]. Younger patients are, presumably due to longer
overall survival, nonetheless subject to a higher risk of
eventual deterioration of bioprosthetic valves, with an
attendant need for reoperation [19, 22–25]. Other factors
which have been reported as being associated with out-
come following RHD-related valve surgery include poorer
pre-operative clinical status, as assessed by New York
Heart Association (NYHA) functional class [26–28] and
impaired pre-operative left ventricular function (left ven-
tricular ejection fraction (LVEF) <45 %) [9, 10, 19]. Pre-
operative AF has also been found to predict later
mortality [16, 26, 29]. Finally the valve involved and the
nature of the valve lesion (regurgitation versus stenosis)
has been shown to influence outcome with the best long-
term outcome seen in those with isolated mitral regurgita-
tion [29].
It has been suggested Indigenous Australians (Aboriginal
Australians and Torres Strait Islander peoples) may have
poorer survival following RHD valve surgery compared
with non-Indigenous Australian patients [16, 25, 26].
Nonetheless previous studies have tended to suffer from a
lack of power, have usually been restricted to single site
and often failed to control for other factors which may in-
fluence survival. Despite tending to be younger at time of
surgery, Indigenous Australians have previously been
found to have poorer survival within the first 30 days fol-
lowing valve surgery [16, 26] and at five years [16, 26, 30].
Where disparities have been noted they have been at-
tributed to a range of factors including comorbidities
[16, 25, 26], barriers to primary and specialist health
care and access, compliance and monitoring of antic-
oagulation during long-term follow-up [23].
Whilst existing national Australian guidelines [25] for
RHD management acknowledge that outcomes may be
affected by treatment choice, prosthetic valve type and
timing of referral for intervention, there remains limited
information regarding how these factors interact and
how they might be anticipated to influence outcomes
and treatment recommendations.
We therefore aimed to identify factors associated with
RHD surgery outcome by analysing data from a large
multi-site cardiac surgery enhanced surveillance register,
The Australia and New Zealand Society of Cardiac and




The Australia and New Zealand Society of Cardiac and
Thoracic Surgeons (ANZSCTS) National Cardiac Surgery
Database is an Australia-wide voluntary database for the
prospective collection and analysis of the results of cardiac
surgery. It collects data from 25 Australian hospitals
on patients who have undergone cardiac surgery, the
types of surgery performed and early (30 day) compli-
cations [31–33] and links this with long-term survival
data.
Analysis
Demographic data including age, gender, location and
Indigenous status were assessed. The remoteness of the
usual place of residence was classified based on the
Australian Statistical Geography Standard [34] as Remote
(Remoteness Area (RA) categories 3 or 4) or non-Remote.
Co-morbidities assessed included chronic kidney disease
(defined as pre-operative estimated glomerular filtration
rate (eGFR) less than 60 mL/min/1.73 m2 based on the
Modification of Diet in Renal Disease (MDRD) equation
[35] and stratified to stages 3 (30 – 59 mL/min/1.73 m2),
4 (15 – 29 mL/min/1.73 m2), and 5 (<15 mL/min/
1.73 m2) [37], previous and current smoking status, con-
comitant coronary artery bypass grafting (CABG) and a
pre-existing clinician diagnosis of diabetes mellitus and
hypertension. The pre-operative status relating to under-
lying heart disease included New York Heart Association
(NYHA) classes I to IV [37], pre-operative atrial fibrilla-
tion (AF), echocardiographic assessment of LVEF stratified
to more than 45 %, 30 to 45 % or less than 30 % and
previous percutaneous balloon valvuloplasty (PBV) or
valve surgery.
Valvular lesions were analysed according to the type
and number of valve(s) affected. Valve-related surgical
procedure data included valve repair or replacement
and in the case of replacement, whether this was a
mechanical or bioprosthetic valve.
Outcomes associated with the immediate post- operative
course included length of time of invasive ventilatory sup-
port and length of intensive care stay (expressed as dichot-
omous variables based on median values), hospital length
of stay in days and the need for re-operation during the
initial admission. Early outcomes within the 30 days fol-
lowing surgery included mortality, stratified as cardiac and
non-cardiac, readmission and other complications (valve
dysfunction, acute kidney injury, new atrial fibrilla-
tion, stroke/TIA, deep sternal wound infection, septi-
caemia, anticoagulation (bleeding, and/or embolic)
complications and heart failure). Finally longer-term sur-
vival beyond 30 days was determined from the National
Death Index (NDI), a database, housed at the Australian
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Institute of Health and Welfare, which contains records of
all deaths occurring in Australia since 1980 [38].
Statistical analysis
Data were analysed using IBM SPSS Statistics 20 (IBM,
New York, USA) and STATA Release 13 (StataCorp LP,
Texas, USA). Descriptive data were summarised using
standard univariate techniques and reported as percent-
ages with 95 % confidence intervals (95 % CI), means with
standard deviation (SD) or medians with interquartile
range (IQR) depending on the data format and distribu-
tion. Comparisons between groups were undertaken using
χ2 for categorical data and Student’s t-Test or Mann–
Whitney U test for continuous Normally distributed or
non-Normally distributed data respectively. A p valve less
than 0.05 was taken to indicate statistical significance and
all tests were two-sided.
Survival analysis for mortality was presented with
Kaplan- Meier curves and analysed using the log rank
test to compare survival in RHD and non-RHD surgery
and Indigenous and non-Indigenous Australian RHD
patients.
Multivariable linear, logistic and Cox proportional
hazard models were developed to identify independent
factors associated with outcome measures. These used a
backwards stepwise approach including in the first model
all factors associated with a particular outcome variable
using bivariate analysis with a p value <0.1. Factors with
a p value > =0.05 were progressively removed from
the models starting with those variables with a regres-
sion co-efficient closest to 0 or an odds (OR) or
hazard (HR) ratio closest to 1. Final models were
limited to predictive factors with significant coefficients
(p < 0.05).
Approval for this project was granted by the Monash
University Human Research Ethics Committee (CF13/
2737 – 2013001472).
Results
Data in relation to 62 707 cardiac surgical procedures
were collated by the ANZCTS database between 1 June
2001 and 31 December 2012. Details regarding the
breakdown of patients included in this database have
been outlined elsewhere [33]. A subset of 17 227 surgical
valve procedures (with or without coronary artery bypass
grafting (CABG)) was included for analysis. Demo-
graphic and comorbidity data relating to these patients
are outlined in Table 1. RHD was a significantly more
common indication for valve surgery in Indigenous
(52.4 %, 95 % CI 46.9 – 57.9) as compared with non-
Indigenous Australians (7.2 %, 95 % CI 6.8 – 7.6 %)
(p <0.001).
Table 1 Descriptive characteristics of valve surgery patients stratified by whether indication for surgery was RHD or non-RHD related [33]
All RHD-related Non-RHD P value
N = 17227 N = 1384 N = 15843
Age (years) (median (IQRa) 71.3(61.2 – 78.3) 59.7(50.9 – 71.4) 71.9(62.3 – 78.6) <0.001
Sex (% female) (95 % CI#) 37.3(36.6 – 38.1) 64.5(61.9 – 67.0) 35.0(34.2 – 35.7) <0.001
Indigenous status (% Aboriginal and Torres Strait Islander people) (95 % CI) 1.9(1.7 – 2.1) 12.6(10.9 – 14.4) 1.0(0.8 – 1.2) <0.001
Concomitant CABG (%, 95 % CI) 39.1(38.4 – 39.8) 21.2(19.1 – 23.5) 40.7(39.9 – 41.4) <0.001
Pre-operative comorbidities
Diabetes (%, 95 % CI) 23.2(22.5 – 23.8) 20.3(18.2 – 22.5) 23.4(22.8 – 24.1) 0.009
Chronic kidney disease (% eGFR < 60 mL/min/1.73 m2) (95 % CI)) 36.7(36.0 – 37.5) 31.2(28.8 – 33.7) 37.2(36.5 – 38.0) 0.814
Hypertension (%, 95 % CI) 67.0(66.3 – 67.7) 53.0(50.3 – 55.7) 68.2(67.5 – 68.9) <0.001
Previous smoking (%, 95 % CI) 53.1(52.3 – 53.8) 52.7(50.0 – 55.3) 53.1(52.3 – 53.9) 0.955
Current smoking (%, 95 % CI) 16.0(15.2 – 16.7) 25.1(22.0 – 28.4) 15.2(14.5 – 16.0) <0.001
Pre-operative status
NYHA classes III & IV (%, 95 % CI) 43.7(42.9 – 44.4) 53.7(51.0 – 56.4) 42.8(42.0 – 43.6) 0.351
Atrial fibrillation (%, 95 % CI) 19.3(18.7 – 19.9) 40.5(37.9 – 43.2) 17.4(16.8 – 18.0) <0.001
LVEF >45 % (%, 95 % CI) 81.2(80.6 – 81.8) 84.6(82.6 – 86.5) 80.9(80.3 – 81.5) 0.001
LVEF 30 – 45 % (%, 95 % CI) 12.1(11.6 – 12.6) 10.9(9.3 – 12.7) 12.2(11.7 – 12.7) 0.154
LVEF <30 % (%, 95 % CI) 4.3(4.0 – 4.6) 2.2(1.5 – 3.2) 4.5(4.2 – 4.8) <0.001
Previous procedures
Valve surgery (%, 95 % CI) 6.4(6.1 – 6.8) 13.5(11.8 – 15.4) 5.8(5.4 – 6.2) <0.001
Percutaneous balloon valvuloplasty (PBV) (%, 95 % CI) 4.9(4.3 – 5.6) 20.7(16.7 – 25.2) 3.3(2.8 – 4.0) <0.001
aIQR – interquartile range, #95 % CI – 95 % confidence intervals
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Over a maximum period of follow-up of 10.5 years
there were 2089 deaths reported, 157 in RHD patients
(11.3 %) and 1932 in non-RHD patients (12.2 %). Data
regarding crude 30 day, 5 year and 10 year survival
stratified by RHD or non-RHD valve surgery are pre-
sented in Table 2.
30 day outcomes
Outcomes within 30 days following surgery are
outlined in Table 3. RHD patients, compared with non-
RHD patients, had a longer period of invasive ventilation
and a higher rate of readmission to hospital but no
difference in 30 day survival. RHD patients were less likely
to have a stroke but were more likely to have an
anticoagulant complication.
Factors independently associated with 30 day mortality
following valve surgery using logistic regression modelling
are listed in Table 4.
Long term survival
Kaplan-Meier curves comparing mortality in RHD and
non-RHD-related valve surgery are shown in Fig. 1. Log
rank testing of mortality in RHD and non-RHD patients
demonstrated a small, but statistically, significant differ-
ence in survival out to 10 years with superior survival in
RHD valve surgery patients.
Factors independently associated with longer term
mortality following valve surgery using Cox proportional
modelling are outlined in Table 5.
Of note was, once these factors were controlled for,
the superior longer term survival associated with RHD
was no longer present. In addition, being Indigenous
Australian, the nature of the valve lesion and the presence
of poorer preoperative LVEF were not independently asso-
ciated with longer-term survival in RHD patients after
controlling for the factors highlighted in Table 5.
Outcome in Indigenous Australians
Indigenous RHD patients, compared with non-Indigenous
RHD patients had a shorter post procedural length of
hospital stay (7 days (95 % CI 6.0 – 10.0) compared to
8 days (95 % CI 7.0 – 12.0)) and were less likely to de-
velop acute kidney injury (2.9 % (95 % CI 1.0 – 6.7)
compared to 6.8 % (95 % CI 5.4 – 8.4)) or AF post-
operatively (13.8 % (95 % CI 8.1 – 21.4) compared to
36.5 % (95 % CI 32.9 – 40.2)).
Thirty day mortality following RHD valve surgery in
Indigenous Australians was comparable to that seen in
non-Indigenous Australians (2.9 % compared with 3.1 %,
p = 0.895). On logistic regression modelling restricted to
Indigenous Australians only two factors were independ-
ently associated with 30 day mortality in those having
RHD valve surgery: chronic kidney disease (OR 14.1,
95 % CI 1.0 – 200.0) and readmission (OR 20.8, 95 % CI
1.5 – 333.3).
Longer term mortality following RHD surgery was also
comparable in Indigenous and non-Indigenous patients
(10.3 % compared with 11.5 %, p = 0.657). Three factors
were independently associated with longer term mortal-
ity in Indigenous Australians using Cox proportional
modelling: LVEF <30 % (HR 31.3, 95 % CI 7.0 – 142.9),
a longer period of ventilation (1.04/additional hour,
95 % CI 1.01 – 1.07), and a shorter initial stay in
hospital (0.5/additional day, 95 % CI 0.3 – 0.8).
Remote location was not a significant predictor of
either short or long term outcome either alone or in as-
sociation with procedure type (log rank test, p = 0.594)
in Indigenous Australians, who were more likely to res-
ide in such locations.
Outcome and procedure type
The relationship between the type of surgical procedure
for RHD-related disease and survival was analysed over
a maximum period of follow-up of 10.5 years. There
were 33 (11.8 %, 95 % CI 8.3 – 16.2, p = 0.775) deaths
reported following RHD-related valve repair (five for
isolated repair without associated other valve surgery),
65 (14.1 %, 95 % CI 11.0 – 17.6, p = 0.024) following
RHD-related bioprosthetic valve replacement (58 for iso-
lated bioprosthetic valve replacement) and 84 (10.1 %,
95 % CI 8.2 – 12.4, p = 0.082) (76 for isolated mechanical
valve replacement) following RHD-related mechanical
valve replacement. A Kaplan-Meier curve comparing
mortality in RHD-related valve repair, bioprosthetic
valve and mechanical valve surgery is shown in Fig. 2
and demonstrated a significant difference in survival
between operative groups. This difference specifically
related to poorer survival following bioprosthetic replace-
ment (HR 1.5 (95 % CI 1.1 – 2.0). Multivariate survival
analysis for these RHD patients (see Table 5) demon-
strated this difference in survival persisted after
controlling for co-existent diabetes and chronic kidney
Table 2 Unadjusted mortality at 30 days, 5 years and 10 years stratified by RHD or non-RHD valve surgery
Mortality number (%, 95 % CI) All valve surgery RHD valve surgery Non-RHD valve surgery RR* (95 % CI) (p value)
30 day 576/13866(4.2, 3.8 – 4.5) 35/1137(3.1, 2.2 – 4.3) 541/12729(4.3, 3.9 – 4.6) 1.38 (0.99 – 1.93)(0.058)
5 year 665/3821(17.4, 16.2 – 18.6) 54/353(15.3, 11.7 – 19.5) 611/3468(17.6, 16.4 – 18.9) 1.15 (0.89 – 1.49)(0.273)
10 year 96/254(37.8, 31.8 – 44.1) 7/28(25.0, 10.7 – 44.9) 89/226(39.4, 33.0 – 46.1) 1.58 (0.81 – 3.05)(0.139)
*RR - Relative risk in RHD-related valve surgery patients compared with non-RHD surgery
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disease, performance status, ventilation time, hospital
length of stay and early septicaemia.
Discussion
This is the largest published study of short and
longer-term outcome following RHD valve surgery in
Australia. Whilst rheumatic valve surgery was rela-
tively uncommon, representing only 8 % of all valve
surgery procedures performed during the study
period, it represented a significant proportion (>50 %)
of valve procedures in Indigenous Australians. Such
findings highlight the higher burden of RHD in
Indigenous Australians. Nonetheless the finding that
7.2 % of valve procedures in non-Indigenous Australians
were for RHD-related valve disease also demonstrates the
remaining importance of residual, and particularly ad-
vanced, RHD in non-Indigenous Australians who
accounted for the greatest overall number of patients.
Much of this RHD in non-Indigenous Australians was
presumably associated with residents who had immigrated
to Australia from countries where RHD remained en-
demic or who had acquired RHD decades before, at a time
when acute rheumatic fever (ARF) remained an issue for
all Australians, rather than predominantly Indigenous
Australians as is the case now [6].
Whilst RHD is a relatively common indication for
valve surgery, it is not a major contributor to overall
mortality in Australia. Nationally, between 2007 and
2009, there were only 897 deaths registered with RHD
as the primary cause of death. This accounted for
0.6 % of cardiovascular and 0.2 % of all deaths [40].
National data nonetheless do not highlight the par-
ticular impact RHD has on Indigenous Australians.
Whilst between 2004 and 2007 there were only 63
deaths from RHD among Indigenous Australians (5.8
per 100,000 population) this rate was 5.2 times greater
than that for non-Indigenous Australians (1.1 per
100,000 population) [39].
Our study highlights that survival following valve sur-
gery in the short (30 days) and longer term is equivalent
in RHD and non-RHD patients. This concurs with Ribeiro
et al’s recent review of 352 Brazilian patients who under-
went mitral valve replacement. In their study RHD was an
indication in 43.5 % of patients and, in similar multivariate
analysis, they demonstrated no significant difference in
long-term survival for RHD-related surgery [40]. Dillon
et al’s Malaysian study of mitral valve repair in RHD and
non-RHD patients [41] also demonstrated no difference in
short and long term survival between these groups. Our
Australian valve surgery patients also had short and
Table 3 Outcome of valve surgery within 30 days
All RHD-related Non-RHD P value
N = 17227 N = 1384 N = 15843
Initial admission
Ventilation (hours) (median (IQR)) 11.0(6.8 – 19.0) 12.0(7.0 – 19.0) 11.0(6.7 – 19.0) 0.009
Intensive care unit (ICU) stay (hours) (median (IQR)) 43.3(23.0 – 72.3) 42.0(23.0 – 70.8) 43.5(23.0 – 72.5) 0.350
Post procedure length of stay (days) (median (IQR)) 8.0(7.0 – 13.0) 8.0(7.0 – 13.0) 8.0(7.0 – 13.0) 0.648
Re-operation for valve dysfunction (%, 95 % CI) 0.2(0.1 – 0.3) 0.4(0.1 – 0.8) 0.2(0.1 – 0.3) 0.152
Re-operation not related to valve dysfunction (%, 95 % CI) 7.0(6.6 – 7.4) 7.3(6.0 – 8.8) 7.0(6.6 – 7.4) 0.652
Mortality
All cause (%, 95 % CI) 4.2(3.8 – 4.5) 3.1(2.2 – 4.3) 4.3(3.9 – 4.6) 0.058
Cardiac cause (%, 95 % CI) 1.5(1.3 – 1.8) 1.5(0.9 – 2.4) 1.5(1.3 – 1.8) 0.122
Non-cardiac cause (%, 95 % CI) 2.7(2.4 – 2.9) 1.6(1.0 – 2.6) 2.8(2.5 – 3.0) 0.907
Readmission (%, 95 % CI) 11.2(10.7 – 11.7) 13.8(12.0 – 15.7) 11.0(10.5 – 11.5) 0.002
Other complications
Readmission for valve dysfunction (%, 95 % CI) 0.2(0.1 – 0.4) 0 0.2(0.1 – 0.4) 0.205
Acute kidney injury (%, 95 % CI) 6.3(5.9 – 6.7) 6.3(5.1 – 7.7) 6.3(5.9 – 6.7) 0.971
New AF (% without prior AF, 95 % CI) 34.2(33.4 – 35.1) 33.3(30.1 – 36.6) 34.3(33.5 – 35.1) 0.564
Stroke/ TIA (%, 95 % CI) 2.4(2.2 – 2.6) 1.6(1.0 – 2.4) 2.5(2.2 – 2.7) 0.044
Deep sternal wound infection (%, 95 % CI) 0.9(0.8 – 1.1) 1.2(0.7 – 1.0) 0.9(0.8 – 1.1) 0.247
Anticoagulant complication (bleeding or embolization) (%, 95 % CI) 1.7(1.5 – 1.9) 2.8(2.0 – 3.7) 1.6(1.4 – 1.8) 0.002
Heart failure (%, 95 % CI) 1.9(1.5 – 2.2) 2.4(1.4 – 3.9) 1.8(1.5 – 2.1) 0.274
Septicaemia (positive blood culture with signs of infection)(%, 95 % CI) 1.6(1.4 – 1.8) 0.4(0.8 – 2.1) 0.6(1.4 – 1.8) 0.476
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long-term survival that was equivalent to earlier cohorts
studies of aortic and mitral valve replacement and repair.
Chiang et al’s US study of survival following aortic valve
replacement [42] found an equivalent 30 day mortality of
3 % and Dillon et al’s Malaysian study of mitral valve re-
pair [41] a comparable mortality of 4.3 % in RHD patients
and 2.0 % in non-RHD patients. The long-term (10 year)
survival found in our study (88.7 %) was at the upper
limit reported by other studies including Chiang (76 %)
[42], Dillon (83-89 %) [41] and Ribeiro (71-74 %) [40].
Neither short nor long term survival was significantly
related to Indigenous status as has been suggested in a
previous study [26].
A range of other factors had also been identified as
being associated with outcome following surgery for ad-
vanced RHD [22–24, 43]. These encompassed factors
associated with the underlying severity of valve disease
[10, 12, 13, 20, 29, 44–48], the procedure undertaken
[8–10, 18, 25, 49–57], social and environmental factors
that may have increased the risk of ARF/RHD and the
risk of complications (e.g. social and environmental dis-
advantage including access to initial surgical and
ongoing primary and specialist health care review) and
patient factors that were independent of RHD (e.g. age
and comorbidities) [8–11, 16, 21, 25, 46, 47, 49, 58–60].
In contrast our study found that many of these factors
were not significant predictors of subsequent short and
long term survival in this large cohort using multivariable
analysis.
In our study, RHD valve surgery patients, compared
to those having valve surgery for non-RHD indications,
were more than twice as likely to have pre-operative
AF. This has previously been found to significantly in-
crease the risk of late death [13, 16, 29, 46] especially
from cardioembolic complications [17]. This greater
level of AF in RHD patients has been reported in previ-
ous studies including in Dillon et al’s review of RHD
and non-RHD related valve repair in Malaysia which
found 36 % of RHD patients undergoing mitral valve
repair had pre-operative AF compared with 25 % of
Table 4 Factors independently associated with 30 day mortality following valve surgery in logistic regression modelling and
variance explained by the model
Odds Ratio (95 % CI) All RHD-related Non-RHD
Age (/additional year) 1.01 (1.00 – 1.02) - -
Female sex - - 1.4 (1.1 – 1.8)
Pre-operative comorbidities
Chronic kidney disease 2.4 (1.8 – 3.2) 4.3 (2.0 – 9.2) 2.6 (2.0 – 3.3)
Pre-operative status
NYHA III & IV 1.7 (1.3 – 2.1) - 1.7 (1.3 – 2.2)
LVEF 30 – 45 % 2.4 (1.8 – 3.2) - 2.4 (1.8 – 3.3)
LVEF <30 % 3.5 (2.4 – 5.1) - 3.6 (2.5 – 5.3)
Mitral valve regurgitation 1.2 (1.1 – 1.3) - 1.2 (1.1 – 1.2)
Mitral valve stenosis 0.9 (0.8 – 0.9) - 0.9 (0.8 – 0.9)
Previous procedures
Valve surgery 2.4 (1.6 – 3.4) 2.5 (1.1 – 5.8) 2.4 (1.6 – 3.5)
Initial admission
ICU stay (>43 h) 0.7 (0.6 – 0.9) 0.3 (0.1 – 0.7) -
Post procedure LOS (/additional day) 0.97 (0.96 – 0.98) - 0.96 (0.95 – 0.97)
Complications within 30 days
Readmission 0.4 (0.3 – 0.7) - 0.4 (0.2 – 0.6)
Re-operation for valve dysfunction - 27.5 (2.2 – 338.9) -
Re-operation not related to valve dysfunction 2.7 (2.0 – 3.8) 3.3 (1.3 – 8.4) 2.8 (2.2 – 3.9)
Acute kidney injury 7.3 (5.5 – 9.8) 7.3 (2.9 – 17.9) 6.9 (5.1 – 9.3)
Stroke/ TIA 4.6 (2.9 – 7.2) - 4.6 (2.8 – 7.4)
Anticoagulant complication 2.9 (1.7 – 5.1) - 2.8 (1.5 – 5.1)
Septicaemia 9.5 (6.1 – 15.27) 9.0 (2.5 – 32.3) 10.2 (6.3 – 16.4)
Explained variance
(Nagelkerke R Square statistic [68]) 24.6 % 24.7 % 25.1 %
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Fig. 1 Cumulative survival following RHD and non-RHD-related valve surgery (log rank test, significant p = 0.047)
Table 5 Factors independently associated with long term mortality following valve surgery in Cox proportional hazard modelling
and the significance of the relationship of the model
Hazard Ratio (95 % CI) All RHD-related Non-RHD
Age (/additional year) 1.03 (1.02 – 1.04) 1.03 (1.01 – 1.05) 1.03 (1.02 – 1.04)
Pre-operative comorbidities
Diabetes 1.4 (1.2 – 1.6) 1.7 (1.1 – 2.5) 1.4 (1.2 – 1.6)
Chronic kidney disease 1.5 (1.3 – 1.7) 1.9 (1.2 – 2.9) 1.4 (1.3 – 1.6)
Pre-operative status
NYHA III & IV 1.3 (1.1 – 1.4) - 1.3 (1.1 – 1.4)
Atrial fibrillation 1.4 (1.2 – 1.6) - 1.5 (1.3 – 1.7)
LVEF >45 % 0.7 (0.6 – 0.8) - 0.7 (0.6 – 0.8)
Operative procedure
Mechanical valve 0.8 (0.7 – 0.9) - 0.8 (0.7 – 0.9)
Valve repair only 0.8 (0.6 – 0.9) - 0.8 (0.6 – 0.9)
Multiple valve surgery - - 1.4 (1.1 – 1.7)
Initial admission
ICU stay (>43 h) 1.2 (1.1 – 1.4) - 1.3 (1.1 – 1.4)
Ventilation time (>11 h) - 1.7 (1.1 – 2.9) -
Post procedure LOS (/additional day) 1.01 (1.00 – 1.01) 1.02 (1.01 – 1.03) 1.00 (1.00 – 1.01)
Complications within 30 days
Readmission 1.4 (1.2 – 1.6) - 1.4 (1.2 – 1.7)
Acute kidney injury 1.9 (1.6 – 2.3) - 1.9 (1.6 – 2.3)
Stroke/ TIA 1.6 (1.2 – 2.1) - 1.7 (1.3 – 2.2)
Septicaemia 2.1 (1.6 – 2.8) - 2.2 (1.6 – 2.9)
Significance of model (based on −2 Log Likelihood) <0.001 <0.001 <0.001
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non-RHD patients [41]. Whilst we demonstrated similar
levels of preoperative and post-operative AF, unlike previ-
ous studies, neither prior nor new post post-operative AF
was an independent predictor of survival. Although this
difference may relate to superior long-term anticoagula-
tion in our setting it was not possible to confirm this
based on the lack of long-term post-operative anticoagula-
tion results in our cohort.
The greater risk of pre-operative AF in our patients
with advanced RHD would nonetheless suggest there
may be differences in the atria between RHD and non-
RHD patients at the time of surgery. Whether this relates
to more advanced valvular dysfunction with attendant in-
creased left atrial volume [61] or other influences on atrial
conduction [62] remains to be seen. Irrespective of its
underlying aetiology and influence on overall survival, this
increased burden of pre-operative AF, will necessarily
translate to an attendant greater need, risk and inconveni-
ence of anticoagulation in some patients and has been
shown to be associated with surgical choice [33].
Under and over anticoagulation following valve sur-
gery is common [22, 43, 49, 63] and has been associated
with thromboembolism, bleeding [1, 30] and poorer sur-
vival [12]. In general, anticoagulation can be suboptimal
in all patient groups, and RHD valve surgery patients in
this study were more likely, compared with non- RHD
patients, to develop an anticoagulant complication. This
appeared to be particularly related to bleeding rather
than the cardioembolic complications of stroke or TIA.
This lesser risk of stroke and greater risk of other
anticoagulant complications would suggest monitoring
and titration of anticoagulation, rather than medication
adherence, is a more important contributor to early post-
operative complications in our RHD patients. More de-
tailed understanding of the adequacy of early post-
operative anticoagulation monitoring and treatment titra-
tion in RHD valve surgery patients will be required to
understand and potentially minimize this increased risk.
Increasing age has been shown, in previous studies, to
be associated with poorer survival [9–11, 21, 47, 58] and
an increased need for reoperation [59]. The greater bur-
den of RHD in younger Indigenous patients has been
highlighted and whilst a younger age at the time of RHD
surgery did have an independent effect on survival
following surgery, Indigenous status did not. Such younger
patients are likely to be eventually at risk of structural
valve deterioration with an attendant greater need for
reoperation [29].
Whilst we could not report on the eventual need for
reoperation in our cohort it is reassuring that in other
studies this risk is relatively small, being required at
10 years in 1.6 % of RHD patients having mitral valve
repair [41], 7.3 % of RHD and non-RHD patients with
mechanical mitral valve replacement [40] and 13.6 % of
RHD and non-RHD patients with bioprosthetic mitral
valve replacement [40]. In a setting where late reoperation
might be expected to be required in up to 15 % of often
younger Indigenous RHD patients it was noted that such
reoperation was associated with increased perioperative
mortality but equivalent longer term survival.
In earlier studies objective (LVEF) and functional
(NYHA) measures of cardiac function have both been as-
sociated with outcome following valve surgery [13, 14, 19].
In this study the adverse impact of poorer LVEF and
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Fig. 2 Cumulative survival following RHD-related valve surgery stratified by procedure type (log rank test, p = 0.001)
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NYHA on short-term survival was demonstrated
when the outcome of all valve surgery was analysed
but not when this was restricted to RHD patients
alone. The failure to demonstrate such an influence
in RHD-related surgery may have been related to our
use of multivariate survival analysis. Poorer LVEF was
nonetheless found to adversely impact longer term
survival when analysis was restricted to Indigenous
Australian patients, perhaps highlighting how commu-
nication and accurate assessment of performance sta-
tus may be difficult in a setting of cultural and
linguistic diversity.
The importance of NYHA functional class as an inde-
pendent predictor of survival in the short (perioperative)
[12–14, 27, 28] and longer term [8–10, 14, 47] has been
demonstrated by numerous studies. Our finding that
poorer preoperative clinical status, based on NYHA class,
was not independently associated with longer term mor-
tality may suggest other cardiac and non-cardiac factors
that influence NYHA-measured function, such as unre-
ported or identified pulmonary hypertension or undiag-
nosed coronary heart disease, may have had an
independent effect on survival. Functional assessment
prior to surgery would therefore appear to have an im-
portant ongoing role in predicting outcome of surgery in
addition to other investigations.
Following discharge, RHD valve surgery patients were
more likely to be readmitted to hospital compared with
non-RHD valve surgery patients. Although not explicitly
recorded, persistent or recurrent rheumatic carditis may
have been important in this setting as both are significant
factors associated with valve replacement [19] and repair
failure [12]. This in part provides the rationale for the
recommendation for long-term secondary antibiotic
prophylaxis following surgery even if the risk of recurrent
ARF is deemed to be low [22, 25, 64].
Chronic diseases were frequent co-morbidities in
patients having RHD and non-RHD surgery. None-
theless it was only chronic kidney disease that was
associated with 30 day mortality in both RHD and
non-RHD patients and more specifically, Indigenous
Australians. Chronic kidney disease and diabetes were
both associated with poor longer term survival in
RHD and non-RHD patients. The adverse effect of
kidney disease on post-operative survival [46, 58] is
well described. In Australia between 2007 and 2009
19 % of people dying from RHD had kidney disease
as a contributing factor [39]. The association between
co-existent diabetes and kidney disease, conditions
commonly seen in Aboriginal and Torres Strait
Islander patients and older Australians, and outcome
following valve surgery highlights how changing
disease profiles in an ageing Australian population
may influence trends in valve surgery outcomes.
Limitations of the study
The multicenter nature of this study poses potential limi-
tations. We have shown a number of differences between
RHD and non-RHD valve surgery patients and factors as-
sociated with short and longer-term outcome following
surgery. The differentiation between a RHD and non-
RHD aetiology for valve disease nonetheless relied on the
opinion of the individual surgical centre and was not con-
firmed by independent sources nor benchmarked against
agreed echocardiographic [5] or pathologic criteria. It is
therefore possible that the stratification of RHD and non-
RHD aetiology may not have always been accurate. Never-
theless the majority of patients came from a relatively
small number of high volume centres which have consid-
erable experience in managing patients with RHD and
thus, it would be assumed, significant skill in differen-
tiating RHD and non-RHD related valve disease.
The relatively small number of Indigenous Australian
patients in this study is also a limitation when undertaking
comparisons with non-Indigenous Australians. This re-
flects the relatively small size of the Indigenous Australian
population, the residual burden of RHD in older non-
Indigenous Australians and the fact the database began
with only a few centres and has only gradually increased
over time [33]. During the early years the sample was
likely to have not been representative of surgical experi-
ence in RHD in Indigenous patients and therefore surveil-
lance of longer term survival in this group of patients will
be required.
The ANZSCTS Database does not collect information
regarding pulmonary pressures and particularly the
presence of pulmonary hypertension. Pulmonary hyper-
tension has been associated with poorer early post-
operative mortality in patients having surgery for mitral
regurgitation both in those with and without left ven-
tricular functional impairment [65]. In addition, even in
patients with mitral valve disease and no overt pulmon-
ary hypertension detected on echocardiography, it has
been shown that in many pulmonary hypertension can
be revealed by exercise and this in turn is associated
with poorer outcome [66, 67]. Thus our inability to in-
clude resting and exercise-related pulmonary hyperten-
sion in our analyses may in part explain the lack of
importance of NYHA functional class and reduced
LVEF, as a predictors of long-term survival.
Conclusion
We have presented short and long term outcome data
relating to 17 227 surgical procedures required for the
management of patients with advanced RHD and non-
RHD related valve disease. RHD valve surgery patients,
compared with non-RHD patients, had a longer period
of invasive ventilation, were more likely to be readmitted
to hospital, develop an anticoagulant complication and
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less likely to have a stroke. Independent predictors of
short term mortality following RHD-related valve sur-
gery were co-existent chronic kidney disease, length of
stay in ICU following surgery, acute kidney injury, anti-
coagulant complication and requiring re-operation for
valve dysfunction. Longer term survival in RHD patients,
out to 10 years, was at the upper end of that reported in
earlier studies and was poorer in those with co-existent
chronic kidney disease and diabetes, and those who re-
quired a longer period of ventilation and stay in hos-
pital following surgery. Of note, being an Aboriginal
Australian and/or Torres Strait Islander, co-existent
chronic disease, pre-existing AF, a greater functional
impairment as assessed by NYHA functional class and
poorer pre-operative LVEF were not independently as-
sociated with outcome.
Thus this large cohort of valve surgery patients dem-
onstrates that short and long term outcomes in Australia
are comparable to other countries. Whilst the choice of
procedure undertaken for the management of advanced
RHD is likely to be best informed by patient preference,
the ability to maintain safe anticoagulation and the
underlying nature of the valve lesion, we have demon-
strated poorer long term survival in those having bio-
prosthetic valve replacements. This may possibly relate
to other factors which we have not assessed or con-
trolled for. Ongoing surveillance of valve surgery in this
setting should consider incorporating long-term assess-
ment of the adequacy of anticoagulation, measures of
baseline exercise tolerance and detailed measurement of
resting and exercise-related pulmonary hypertension.
These may provide additional insight into why AF is not
an independent predictor of outcome, how neither
poorer NYHA class nor LVEF influences survival and
why bioprosthetic valves may be associated with poorer
long term survival. Together they may better inform
how best to manage AF and the timing and nature of
surgery for advanced RHD.
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